Malfetano JH. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 39:82–84,1990.
Miller AB. Risk/benefit considerations of antiestrogen/estrogen therapy in healthy postmenopausal women. Prev Med 20:79–85,1991.
Paffenbarger RS, Fasal E, Simmons ME et al. Cancer risk as related to the use of oral contraceptives during fertile years. Cancer 39:1887,1977.
Prentice RL. Tamoxifen as a potential preventive agent in healthy postmenopausal women. JNCI 82:1310–1311, 1990.
Ravnihar B, Seigel DG, Linder J. An epidemiologic study of breast cancer and benign breast neoplasias in relation to oral contraceptives and estrogen use. Eur J Canc 15:395, 1979.
Romieu I, Berlin JA, Colditz G. Oral contraceptives and breast cancer. Review and meta analysis. Cancer 66:2253–63, 1991.
Chachter LP, Rosencweig M, Canetta R, et al. Overview of hormonal therapy in advanced breast cancer. Semin Oncol 17 (suppl 6):38–46, 1990.
Spicer D, Pike MC, Henderson BE. The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer. Oncology-Williston-Park 4:49–54, 1990
Vessey MP, Doll R, Sutton PM. Oral Contraceptives and breast neoplasia: A retrospective study. Br Med J 3:719, 1972.
Herbst AL. Gestational trophoblastic disease, in Comprehensive Gynecology, 2nd edition. Herbst AL, Mishell DR, Stenchever MA, and Droegemueller W (editors). Mosby-Year Book, Inc., St. Louis, 1992.
Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer 38:1373, 1976.
Curry SL, Blessing J, DiSaia P et al. A prospective randomized comparison of methotrexate, actinomycin D, and chlorambucil (MAC) versus modified Bagshawe regimen in "poor prognosis" gestational trophoblastic disease. Gynecol Oncol 26:407, 1987.
Jacobs PA, Szulman AE, Funkhouser J et al. Human triploidy: relationship between parental origin of the additional haploid complement and development of partial hydatidiform mole. Ann Hum Genet 46:223, 1982.
Li MC, Hertz R, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 93:361, 1956.
Lurain JR, Brewer JI. Treatment of high-risk gestational trophoblastic disease with methotrexate, actinomycin D, and cyclophosphamide chemotherapy. Obstet Gynecol 65:830, 1985.
Lurain JR, Brewer JI, Torok EE et al. Natural history of hydatidiform mole after primary evacuation. Amer J Obstet Gynecol 145:591, 1983.
Morrow P, Nakamura R, Schlaerth J et al. The influence of oral contraceptives on the postmolar human chorionic gonadotropin regression curve. Amer J Obstet Gynecol 151:906, 1981.
Vaitukaitis JL, Braunstein GD, Ross GT. Radioimmunoassay which specifically measures human chorionic gonadotropin in the presence of human luteinizing hormone. Amer J Obstet Gynecol 113:751, 1972.
Wong LC, Choo YC, Ma HK. Modified Bagshawe's regimen in high-risk gestational trophoblastic disease. Gynecol Oncol 23:87, 1986.
Yordan EL Jr, Schlaerth J, Gaddis O et al. Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system. Obstet Gynecol 69:627, 1987.